Gut

Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide, largely due to the limited efficacy of ...

ORYZON to Sponsor First Phelan-McDermid Syndrome (PMS) Burden of Illness Study

Study led by CureShank Aims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system MADRID and ...
Santé log

Italfarmaco Announces Exclusive Distribution Agreement with Multicare Pharma for DMD Treatment Givinostat in Brazil

Italfarmaco has entered into an agreement with Multicare for the regulatory approval and distribution of givinostat as a treatment for Duchenne muscular dystrophy in Brazil.

ORYZON to Participate in Upcoming Events in September and October

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will participate at the ...

ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that the European Patent Office (EPO) has issued a ...